Lupus
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Published in Clinical Trials Week, May 12th, 2008
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced that its lead product candidate, R788, has successfully treated lupus prone mice and significantly improved their survival as reported in a recently published study of the drug candidate. R788 (fostamatinib disodium) is an orally bioavailable syk kinase inhibitor, which has shown clinically significant results in treating patients with rheumatoid arthritis and immune thrombocytopenic purpura in clinical trials. A third clinical trial of R788 in patients with B-cell lymphoma will be completed later this year. Rigel also expects to initiate a Phase 2 clinical trial in lupus in the second half of 2008.
The study, which...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2008-05-12)
More Articles from Clinical Trials Week
- Clinical Trial Research
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845 - Diabetes
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections - Lung Cancer
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer - Memory Pharmaceuticals Corp.
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 - Nymox Pharmaceutical Corporation
Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia - Acute Myelogenous Leukemia
Reports outline acute myelogenous leukemia research from University of Medicine and Dentistry of New Jersey - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
